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ABSTRACT 
 
Alzheimer’s disease (AD) progressively impairs cognitive and functional 
abilities. Research on pharmacological treatment of AD is shifting to earlier forms of the 
disease, including preclinical stages. However, assessment methods traditionally used in 
clinical research may be inappropriate for these populations. The Alzheimer Disease 
Assessment Scale-cognitive (ADAS-cog), a commonly used cognitive battery in AD 
research, is most sensitive in the moderate range of cognitive impairment. It focuses on 
immediate recall and recognition aspects of memory rather than retention and delayed 
recall. As clinical trials for dementia continue to focus on prodromal stages of AD, 
instruments need to be retooled to focus on cognitive abilities more prone to change in 
the earliest stages of the disease. One such domain is delayed recall, which is 
differentially sensitive to decline in the earliest stages of AD. A supplemental delayed 
recall subtest for the ADAS-cog is commonly implemented, but we do not know 
precisely where along the spectrum of cognitive dysfunction this subtest yields 
incremental information beyond what is gained from the standard ADAS-cog. An item 
response theory (IRT) approach can analyze this in a psychometrically rigorous way. 
This study’s aims are twofold: (1) to examine where along the AD spectrum the delayed 
recall subtest yields optimal information about cognitive dysfunction, and (2) to 
determine if adding delayed recall to the ADAS-cog can improve prediction of 
functional outcomes, specifically patients’ ability to complete basic and instrumental 
activities of daily living. 
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Results revealed differential functioning of ADAS-cog subtests across the 
dimension of cognitive impairment. The delayed recall subtest provided optimal 
information and increased the ADAS-cog’s measurement precision in the relatively mild 
range of cognitive dysfunction. Moreover, the addition of delayed recall to the ADAS-
cog, consistent with my hypothesis, increased covariation with instrumental but not basic 
activities of daily living. These findings provide evidence that the delayed recall subtest 
slightly improves the ADAS-cog’s ability to capture information about cognitive 
impairment in the mild range of severity and thereby improves prediction of 
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1. INTRODUCTION AND LITERATURE REVIEW 
 
Alzheimer's disease (AD) is a progressive, neurodegenerative disease that is 
estimated to currently afflict 5.4 million Americans and up to 26.6 million people 
worldwide (Alzheimer’s Association, 2012; Chamberlain et al., 2011; National Plan to 
Address Alzheimer’s Disease, 2012). Incidence rates double every five years after age 
65, so that AD affects about six percent of those between the ages of 65 and 74, but 
approximately 46 percent of adults 85 and older (Alzheimer’s Association, 2012; 
Mendez & Cummings, 2003). The prevalence of AD worldwide is estimated to 
quadruple by 2050 (Chamberlain et al., 2011), and with the rapidly increasing older 
population (from 40 million in 2010 to a projected 72.1 million in 2030; Alzheimer’s 
Association, 2012), AD is clearly a major societal concern. The U.S. Department of 
Health and Human Services recently developed the National Plan to Address 
Alzheimer’s Disease, stimulated by President Barack Obama signing into law the 
National Alzheimer’s Project Act on January 4, 2011. The National Plan sets forth the 
goal of developing effective forms of prevention and treatment of AD by 2025. These 
federal initiatives have brought AD to the forefront of national attention and mirror the 
drive within the field to better detect preclinical forms of AD, including mild cognitive 
impairment (MCI; Morris et al., 2001) and even earlier preclinical stages. Being able to 
better detect these prodromal stages will aid in earlier treatment of cognitive impairment 
and strengthen understanding of the AD process, with the eventual goal of prevention. 
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To ultimately achieve these goals of effective treatment and prevention of AD, it 
is important to understand that the disease is dimensional and progressive, as it 
increasingly impairs not only neuroanatomical integrity but also cognitive, behavioral, 
and functional domains.  The course of AD is marked by a long preclinical period, 
during which a gradual decline in episodic memory typically occurs (Riepe, Janetzky, & 
Lemming, 2011). The earliest stage is characterized by subjective memory impairment 
(SMI; i.e., memory complaints), which has recently been shown to be a predictor for 
future development of a dementing condition. Approximately 10% of individuals with 
SMI converted to MCI over a three-year period in one study (Jessen et al., 2010). Recent 
work also has revealed differences in functional and structural brain imaging between 
individuals in their 60s with or without SMI (Scheef et al., 2012). The individuals with 
SMI showed hypometabolism in the right precuneus as well as hypermetabolism in and 
reduced volume of the right hippocampus, two neuroanatomical regions associated with 
pathophysiological processes in AD. Moreover, these SMI individuals showed 
differentially greater longitudinal declines in their performances on episodic memory 
tests relative to participants without SMI (Scheef et al., 2012). This recent work has 
established support for SMI as the earliest prodromal stage of the AD spectrum.  
As memory continues to decline and patients move into the MCI and dementia of 
the Alzheimer type (DAT) stages, memory impairment is followed by deficits in 
attention, language, visuospatial orientation, and executive functions (Riepe et al., 2011). 
Language impairment includes word-finding difficulties, with later problems in 
spontaneous speech, comprehension, and vocal repetitions of words or sounds (Mendez 
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& Cummings, 2003). Visuospatial deficits include difficulties in copying figures and 
orienting oneself to one’s environment (e.g., getting lost). Attentional and executive 
dysfunction in part affects planning, abstract reasoning, insight, working memory, 
sustained and divided attention, and inhibition of responses. Impairment in praxis 
typically occurs in the middle to late stages of the disease process and is evident by 
problems performing overlearned motor behaviors, such as brushing one’s teeth or 
dressing oneself (Mendez & Cummings, 2003). AD also produces behavioral symptoms, 
including mood changes, agitation, delusions, aberrant motor behaviors, and sleep 
disturbances in almost all patients at some point in the disease (Gauthier et al., 2010). 
Moreover, patients with AD demonstrate subtle difficulties in instrumental activities of 
daily living (IADLs; e.g., driving, finances, medication management) as early as MCI 
(Griffith et al., 2003; Perneczky et al., 2006), with progressively greater impairments in 
IADLs and ultimately in more basic activities of daily living (ADLs; e.g., eating, 
bathing, toileting behaviors) as the disease progresses. In the most severe and latest 
stages of the disease, AD patients are unable to care for themselves and are entirely 
dependent upon others (Mendez & Cummings, 2003).   
Because AD is an ever-evolving entity, accurate and appropriate assessment 
varies across the disease spectrum.  For example, early in the course of the disease, even 
preclinically, subtle neuropsychological deficits can be detected in full cognitive 
batteries, but functional impairments are relatively subtle.  However, in the latest stages 
of the disease, patients typically cannot respond meaningfully to cognitive batteries, so 
appropriate assessment often consists of behavioral ratings, brief cognitive screenings, 
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and physical self-maintenance measurement (Hermann & Gauthier, 2008). The 
progressive nature of AD can make evaluating the impact of disease-modifying 
treatments difficult.  Multiple outcome measures are typically used, including 
assessments of cognitive functioning, daily functional impairments, neuropsychiatric 
symptoms, clinician ratings, and caregiver burden.  In terms of cognitive functioning, the 
“gold standard” for assessment in clinical research has historically been the Alzheimer's 
Disease Assessment Scale-cognitive (ADAS-cog; Mohs, Rosen, & Davis, 1983; Rosen, 
Mohs, & Davis, 1984; Kirk, 2007; Rockwood, Fay, Gorman, Carver, & Graham, 2007).  
The ADAS-cog, which assesses basic linguistic, memory, orientation, and praxis 
functions, was specifically designed for use in moderate AD and has been shown to be 
most sensitive to impairment in cognitive functioning in the moderate stages of the 
disease (Benge, Balsis, Geraci, Massman, & Doody, 2009). Benge and colleagues (2009) 
determined that the ADAS-cog discriminates best at moderate levels of Alzheimer’s, 
specifically between -1.00 and 1.74 standard deviations (SDs) of cognitive impairment in 
a largely demented sample. Similarly, research has shown a curvilinear relationship 
between dementia severity and ADAS-cog scores (Benge et al., 2009; Ito et al., 2011), 
so that there must be relatively large changes in cognitive dysfunction at the mild and 
severe stages of AD before the ADAS-cog scores reflect those changes. However, in the 
moderate stages of AD, ADAS-cog scores are sensitive to smaller differences in 
cognitive dysfunction. Other studies have found a nonequivalent rate of longitudinal 
change in ADAS-cog scores across different stages of the AD spectrum. Irizarry and 
colleagues (2008) found that a moderate AD group had a 24-week change in ADAS-cog 
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score of 2.99 points, but a mild AD group had a change score of 0.19 points, indicating 
minimal change in the mild group but larger change in the moderate AD group. Over a 
12-month period, patients with moderate AD at baseline declined more on the total score 
and most individual subtests than did the patients with mild AD (Sevigny, Peng, Liu, & 
Lines, 2010). In another 12-month longitudinal study, patients with mild and moderate 
AD showed a similar change in their ADAS-cog total scores at one-year follow-up, but 
the patients with severe AD had notably less change in their ADAS-cog score (Suh, Ju, 
Yeon, & Shah, 2004), which is likely indicative of a floor effect. These results reveal the 
nonlinearity of the ADAS-cog across the AD spectrum, so that changes in observed 
scores over time do not represent equivalent changes in underlying cognitive impairment 
along the dimension of disease severity. The ADAS-cog is most sensitive to smaller 
changes in cognitive functions in the moderate stages of dementia but is not as good at 
capturing information about cognitive dysfunction in the mild and severe stages of AD. 
Because the ADAS-cog was designed to measure cognitive dysfunction in the 
moderate stages of AD, it focuses on immediate recall and recognition aspects of 
memory rather than retention and delayed recall of information. However, as AD clinical 
trials and basic AD research increasingly focus on preclinical or prodromal stages of 
AD, instruments need to be retooled to focus on the cognitive abilities that are more 
prone to change in the earliest stages of the disease. One such domain is delayed recall, 
or ability to retain and retrieve information that was previously learned after a delay.  
Numerous studies have demonstrated that delayed recall is differentially sensitive to 
decline in the earliest stages of AD (cf., Chen et al., 2000; Fleisher et al., 2007; 
  6 
Gallagher et al., 2010; Pozueta et al., 2011; Rabin et al., 2009; Rami et al., 2012; Tabert 
et al., 2006). However, the ADAS-cog eschews a measure of delayed recall in favor of 
more immediate recall. Considering its design for use in moderate AD, this was 
originally warranted, given the prominent deficits in learning and immediately recalling 
information later in the disease course.  Yet to adequately track the disease across its 
course, this important domain of delayed recall must be assessed when conducting 
research with patients in the mild and preclinical stages of AD.    
In an attempt to bolster the ADAS-cog’s appropriateness for use with patients in 
the earlier stages of the AD spectrum, additional subtests are sometimes used with this 
test, including a delayed recall subtest (Mohs et al., 1997). Research shows that the 
delayed recall subtest strengthens the ability to discriminate between controls, patients 
with MCI, and patients with DAT (Grundman et al., 2004; Llano, Laforet, & 
Devanarayan, 2011; Petersen et al., 2010). Addition of the delayed recall subtest also 
may increase power to predict patient conversion from MCI to DAT (Fleisher et al., 
2007; Llano et al., 2011). Sano and colleagues (2011) found that the inclusion of the 
delayed recall subtest strengthened the ability to detect longitudinal cognitive change in 
an MCI group, but it was not useful in DAT groups, even among those with mild 
dementia. Performance on delayed recall changed at a similar rate over 12 months for 
both the MCI and DAT groups. However, when the researchers examined a standardized 
index of change (12-month change in score/SD of change), they found that the inclusion 
of delayed recall increased sensitivity to longitudinal cognitive decline in the MCI group 
but not in the DAT group. They suggested that the insensitivity to cognitive change over 
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time in the DAT group was due to floor effects, such that the DAT patients already 
performed poorly on this subtest at baseline, so there was very little room for decline on 
the test over the 12-month period. In contrast, delayed recall was able to increase 
sensitivity to cognitive change in the MCI group because they were not as impaired at 
baseline and had more potential for decline to occur on the subtest. Considering these 
findings, then, the delayed recall subtest appears to strengthen the discriminative and 
predictive power of the ADAS-cog, particularly at the milder stages of the AD spectrum. 
Although we know that adding delayed recall to the ADAS-cog can help 
distinguish between different groups along the AD spectrum and can aid in predicting 
longitudinal decline, we do not know precisely where along the spectrum of cognitive 
dysfunction (e.g., in the mild or moderate ranges) the delayed recall subtest yields 
incremental information beyond what is gained from the standard ADAS-cog. Based on 
findings discussed above that delayed recall improved sensitivity to longitudinal change 
in MCI but not DAT groups (Sano et al., 2011), it would seem that delayed recall likely 
provides information about cognitive dysfunction in the mild or preclinical stages of the 
AD spectrum. However, this speculation—self-evident as it may seem—has not been 
psychometrically analyzed. To do so, research needs to be conducted to examine how 
the delayed recall subtest functions across the continuum of AD-related cognitive 
dysfunction. This would provide psychometrically based information about where along 
the AD spectrum delayed recall can enhance the functioning of the ADAS-cog, 
discriminate between degrees of severity, and strengthen power for predicting 
longitudinal change.  
  8 
An item response theory (IRT) approach provides a framework to analyze these 
issues. IRT takes into account the differential ability of each ADAS-cog subtest to relate 
to the latent construct (in this case, AD-associated cognitive dysfunction) along the 
spectrum of the disease. At any given point along the AD spectrum, particular ADAS-
cog subtests may be more sensitive to and better able to capture information about 
cognitive dysfunction than other subtests. For example, in the moderate stage of AD, it 
could be that immediate recall of a list of words is strongly related to overall cognitive 
dysfunction while expressive speech is weakly related. Expressive speech might be 
strongly related to cognitive dysfunction in the later stages of AD, so it can provide more 
information about the latent construct among patients in the severe stages of AD but not 
as much information in the moderate stages. Similarly, word recall might be weakly 
related to cognitive dysfunction in the severe stages of the disease because of the floor 
effects of the test; patients with severe DAT are likely so impaired that they cannot recall 
any words on the subtest, so it cannot provide any discriminative information about 
dementia severity because everyone is performing the same. However, by weighting all 
subtests equally and summing them to gain a total score, we lose this information about 
cognitive impairment. Therefore, by using an IRT framework, we can determine where 
along the AD spectrum the delayed recall subtest can most optimally provide 
information about cognitive dysfunction and how its addition to the ADAS-cog changes 
the test’s discriminative and predictive power. My first hypothesis is that the delayed 
recall subtest will be most sensitive to cognitive dysfunction in the mild stages of the AD 
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spectrum and so by adding delayed recall to the ADAS-cog, the test as a whole will 
better be able to discriminate between gradations of severity in this mild range. 
The goals of increasing measurement precision and psychometrically 
determining where along the AD spectrum delayed recall provides information are 
critical to better enable research focused on detecting and treating AD-related cognitive 
impairment in the earliest stages. Being able to more precisely and accurately measure 
severity of cognitive impairment across the entire spectrum of the disease will likely 
strengthen ability to predict other important outcomes, such as predicting conversion 
from MCI to dementia and even from SMI to MCI. In addition, adding delayed recall to 
the ADAS-cog may strengthen its ability to predict functional impairment. Impairment 
in IADLs and ADLs progressively disables AD patients and is associated with global 
cognitive dysfunction. Deficits in IADLs include difficulties with more complex daily 
activities, such as driving, managing medications, handling finances, operating the 
telephone, and taking care of household needs (e.g., shopping, cleaning, cooking). 
Difficulties in these IADLs develop relatively early in the disease process, such that at 
least subtle problems in IADLs are often present in the MCI stage (Griffith et al., 2003; 
Perneczky et al., 2006). Assessment of these impairments in IADLs can improve 
prediction of future conversion to DAT (Gold, 2012; Luck et al., 2012; Rozzini et al., 
2007). Impairments in basic ADLs occur later in the disease process, typically in the 
moderate to late stages (Hermann & Gauthier, 2008). ADLs include more basic 
functions, including bathing, dressing, eating, and toileting behaviors. This study will 
examine whether adding delayed recall to the ADAS-cog will strengthen its ability to 
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detect the association between cognitive dysfunction and these two classifications of 
functional impairments (i.e., IADLs and ADLs), which in turn can better inform clinical 
research on effective treatments for the range of deficits in AD, including cognitive and 
functional variables. My second hypothesis is that adding delayed recall to the ADAS-
cog will improve its ability to detect an association between cognitive dysfunction and 
IADLs, but the inclusion of delayed recall will have a negligible impact on ability to 
detect the association between cognitive dysfunction and ADLs. 
In sum, this study’s aims are twofold: (1) to examine where along the AD 
spectrum the delayed recall subtest yields optimal information about cognitive 
dysfunction, and (2) to determine if adding delayed recall to the ADAS-cog can improve 
prediction of functional outcomes, specifically patients’ ability to complete ADLs and 
IADLs. My first hypothesis is that the delayed recall subtest will add incremental 
information about cognitive dysfunction in the mildest stages of the AD spectrum and 
thus will improve the ability of the ADAS-cog as a whole to capture information about 
cognitive dysfunction in these mild ranges. Because IADLs are subject to decline in 
early AD but ADLs do not typically decline until later in the disease process, my second 
hypothesis is that adding delayed recall to the ADAS-cog will increase the ability to 
detect the association between cognitive dysfunction and IADLs but not basic ADLs. 
 
  




 Participants were 788 patients who presented with memory complaints to the 
Baylor College of Medicine Alzheimer’s Disease and Memory Disorders Center 
(ADMDC) in Houston, Texas. Ages at baseline ranged from 39 to 94 (M = 74.36, SD = 
8.26 years) with mean level of education of 14.47 years (SD = 5.46 years). Sixty-one 
percent (n = 483) were female and 93.4% (n = 736) were White, with other races 
represented including African-American and Asian-American. Patient diagnoses 
included probable AD with DAT (n = 593, 75.3%), possible AD with DAT (n = 61, 
7.8%), mixed AD with DAT (n = 53, 6.7%), amnestic MCI (n = 58, 7.4%), and SMI (n = 
22, 2.8%). These diagnoses were included because they represent the full AD spectrum, 
from prodromal stages (SMI, MCI) to DAT. 
2.2 Materials and Procedures 
Patients completed a comprehensive evaluation at baseline admission and annual 
follow-up examinations, including neurological, neuropsychological, and medical 
testing. As part of this longitudinal protocol, patients completed the ADAS-cog. As 
described earlier, this instrument assesses AD-associated cognitive dysfunction across 
11 subtests. Subtests can be grouped into three domains of functions: memory 
(immediate word recall, recognition, remembering test instructions, orientation), 
language (commands, naming, expressive speech, language comprehension, word 
finding), and praxis (construction, ideational praxis). Patients also completed the delayed 
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recall subtest. Raw scores for subtests are summed to create a total score, with higher 
scores indicating more errors and greater cognitive dysfunction. Total scores for the 
standard, 11-item ADAS-cog (ADAS-cog11) range from 0 (minimal impairment) to 70 
(severe impairment). The delayed recall subtest has a total possible score of 10, so total 
ADAS-cog scores including the 11 standard subtests and the delayed recall subtest 
(ADAS-cog12) range from 0 to 80. Patients’ most recent ADAS-cog11 and ADAS-
cog12 scores were used to avoid oversampling from the preclinical and mild stages of 
AD by using baseline data. 
For each patient, a collateral source such as a spouse or caregiver completed two 
questionnaires regarding the patient’s ability to complete ADLs and IADLs. The 
Physical Self-Maintenance Scale (Lawton & Brody, 1969) measures six domains of 
basic ADLs, including toileting, dressing, eating, grooming, ambulation, and bathing 
behaviors. Patient’s ability to complete these activities are scored on a 1-to-5 point scale, 
where a score of 1 indicates no problems completing these activities and 5 indicates 
severe impairment in completing these functions. Possible total scores range from 6 (no 
impairment) to 30 (severe impairment). In this sample, total scores ranged from 6 to 28 
(M = 11.03, SD = 5.01). The Instrumental Activities of Daily Living Scale (Lawton & 
Brody, 1969) assesses patients’ ability to independently operate a telephone, take care of 
shopping needs, prepare meals, perform housekeeping duties, complete laundry, manage 
transportation needs, take medications properly, and handle finances. For each domain, 
the patient’s ability to complete these activities was scored on a 0-to-3, 0-to-4, or 0-to-5 
Likert-type scale, where a low score indicates no impairment and a high score indicates 
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severe impairment in completing that activity. For select domains (i.e., food preparation, 
housekeeping, laundry, ability to handle finances, medications), a score of 0 could be 
selected if the domain was not applicable, such as if the patient was never responsible 
for managing finances or is not currently taking medications. Possible total scores range 
from 3 (no impairment) to 31 (severe impairment). In this sample, total scores ranged 
from 5 to 31 (M = 21.12, SD = 6.84). 
Medical diagnoses were based on a consensus conference review of medical 
records, neuropsychological test scores, and medical evaluations. Additional information 
on the ADMDC protocol can be found elsewhere (Doody et al., 2005). 
2.3 Data Analyses 
For my first hypothesis, an IRT framework provides the best way to examine 
how the ADAS-cog and its subtests function along the continuum of cognitive 
dysfunction. IRT analyses assume unidimensionality of the latent construct (in this case, 
AD-associated cognitive dysfunction). Although the ADAS-cog measures different 
conceptual constructs (e.g., memory, language, praxis), unidimensionality reflects the 
tendency of those constructs to covary enough that they represent just one statistical 
factor. To test for unidimensionality, I conducted exploratory and confirmatory factor 
analyses in SPSS v. 13.0 and MPLUS (Muthen & Muthen, 2007) and examined 
goodness-of-fit indices. 
 IRT analyses were run in Multilog v. 6.3 (Thissen, 1991). Using Samejima’s 
(1969) graded response model, I estimated parameters for each ADAS-cog item (i.e., 
subtest). Each item has an a (discrimination) parameter, which indicates how related the 
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item is to the latent construct (i.e., cognitive dysfunction, denoted as theta ‘θ’). Theta is 
represented by standardized z-scores from -4.00 to 4.00, with a mean of 0 and a SD of 1, 
where negative scores indicate milder degrees and positive scores represent more severe 
degrees of cognitive impairment. Values of a parameters typically range from 0 to 3 
(Fraley, Waller, & Brennan, 2000; Gray-Little, Williams, & Hancock, 1997; Hambleton, 
Swaminathan, & Rogers, 1991), with higher values indicating greater strength of the 
relationship between the item and theta. Each item has multiple b (difficulty) parameters, 
which indicate the severity of cognitive dysfunction that is required for certain response 
options on that item to be endorsed. The a and b parameters define how each item 
functions across the continuum of cognitive dysfunction. 
 To visually inspect how the items and the test function across the dimension of 
cognitive impairment, I created item and test characteristic curves for the ADAS-cog12. 
These curves can be used to predict a patient’s score on a subtest or the entire ADAS-
cog based on underlying severity of cognitive impairment. Alternatively, given a 
patient’s test score, these curves can be utilized to estimate the patient’s degree of 
cognitive impairment. The slope of the curves represents sensitivity of the test or subtest 
to differences in underlying cognitive dysfunction. Steeper slopes indicate a close 
relationship between test scores and small degrees of change in cognitive impairment, 
whereas flatter slopes indicate that somewhat larger degrees of change in cognitive 
dysfunction are necessary before the test score reflects these differences. Examination of 
these curves provides information about where along the dimension of the latent 
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construct each subtest and the ADAS-cog as a whole are most sensitive to gradations of 
cognitive impairment.  
I also created test information curves for the ADAS-cog11 and ADAS-cog12. 
Examination of these curves reveals that maximum information about the latent 
construct (i.e., cognitive dysfunction) is provided at the peak of the curve. These two 
curves can be contrasted to determine how adding delayed recall to the ADAS-cog 
impacts its measurement precision along the spectrum of cognitive dysfunction.  
 For my second hypothesis, hierarchical regressions were performed to examine 
unique variance accounted for by the ADAS-cog delayed recall subtest in predicting 
functional outcomes. I first entered ADAS-cog11 then delayed recall as independent 
predictors of ADLs. The same method was repeated with IADLs as the dependent 
variable. I also performed a regression with ADAS-cog12 as the predictor of IADLs. 
These regressions permit examination of unique variance in functional outcomes 
accounted for by the delayed recall subtest, ADAS-cog11, and ADAS-cog12.  
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3. RESULTS 
 
3.1 IRT Assumptions 
Exploratory and confirmatory factor analyses supported the unidimensionality of 
the ADAS-cog12. An exploratory factor analysis using maximum likelihood estimation 
revealed a first factor with an eigenvalue of 6.91 and a second factor with an eigenvalue 
of 1.19, accounting for 54.60% and 5.95% of the variance, respectively, with all other 
eigenvalues less than 1.00. The ratio between the first and second eigenvalues was 
5.81:1. Visual examination of the scree plot (see Figure 1) reveals a clear break between 
the first and second factors. Items 1 through 11 (i.e., standard ADAS-cog items) had 
loadings between 0.68 and 0.81 onto the first factor, whereas item 12 (i.e., delayed 
recall) had a weaker loading onto the first factor (0.28). A meta-analysis of factor 
analyses on psychological and behavioral data produced an average factor loading of 
0.32 (Peterson, 2000), so the loading of item 12, although notably smaller than the factor 
loadings for the other items, is approximately average for behavioral data. The delayed 
recall subtest may be tapping into a dimension of dementia severity that is slightly 
different than the dimension captured by the standard ADAS-cog items, but it loads 
strongly enough onto this first factor to justify statistical treatment of the ADAS-cog12 
as a one-factor model and to proceed with IRT analyses.  
 A confirmatory factor analysis using a robust weighted least squares estimation 
also revealed an adequate fit of the data to a one-factor model. The Tucker-Lewis index 
was 0.97 and the comparative fit index was 0.87. The values of these indices reach a  
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Figure 1. Scree plot for the ADAS-cog12 
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sufficient threshold to confirm the proposed model (i.e., a one-factor model). Although 
the comparative fix index is somewhat less than Hu and Bentler’s (1999) recommended 
value of 0.95, this suggested cut-off point has not been well explored in data like these. 
Moreover, recent work has shown particular susceptibility of this fit index to being 
influenced by smaller factor loadings on exploratory factor analysis (Heene, Hilbert, 
Draxler, Ziegler, & Buhner, 2011). Therefore, these fit indices are sufficient to 
demonstrate an adequate fit between the data and the proposed one-factor model. 
3.2 Item and Test Functioning 
 IRT analyses were conducted on the ADAS-cog12 items. The a parameters 
ranged from 1.65 to 2.86, with b parameters ranging from -3.29 to 2.59. For item 12 
(delayed recall), the a parameter was 1.68 and b parameters ranged from -3.16 to -0.98. 
 Item characteristic curves (ICCs) enable visual analysis of how the items 
function across the dimension of cognitive impairment. Items have been grouped by 
cognitive domain (i.e., memory, language, and praxis), with curves depicting how each 
domain functions across the spectrum of cognitive dysfunction (see Figure 2). In a visual 
analysis of the curves, the part of the curve with the steepest slope indicates that the 
domain has the greatest discriminative power at that given range of theta. To examine 
the memory items in more detail, ICCs for the memory subtests are shown in Figure 3. 
Examination of the delayed recall ICC (see Figure 3) reveals that it is most sensitive in 
the mild range of the disease spectrum.  
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Figure 2. ADAS-cog domain curves  
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Figure 3. Item characteristic curves for ADAS-cog12 memory items 
 
  
  21 




  22 
Figure 5. Test information curves for the ADAS-cog11 and ADAS-cog12 
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These domain curves were combined to produce a test characteristic curve for the 
ADAS-cog12 (see Figure 4), which shows how the test as a whole functions across the 
range of cognitive impairment. A test information curve for the ADAS-cog12 was 
derived from this test characteristic curve (see Figure 5). The information curve visually 
depicts where along the dimension of AD-associated cognitive impairment the test yields 
optimal information. Maximum information about the latent construct (i.e., cognitive 
dysfunction) is provided at the peak of the curve. A test information curve for the 
ADAS-cog11 was also plotted (see Figure 5) to contrast information gained from the 
standard ADAS-cog and the ADAS-cog12. This permits evaluation of how the addition 
of delayed recall changes the ADAS-cog’s functioning across the dimension of cognitive 
impairment. Visual inspection indicates that the ADAS-cog12 provides more 
information in the relatively mild range of the AD spectrum than does the ADAS-cog11. 
These results confirm my first hypothesis that adding delayed recall to the ADAS-cog 
increases sensitivity to cognitive impairment in the mild range of AD, but in a less 
robust manner than expected. 
3.3. ADAS-cog and Functional Impairment  
 Hierarchical regressions were conducted to examine the second hypothesis that 
adding delayed recall to the ADAS-cog will increase the ability to detect the association 
between cognitive dysfunction and IADLs but not basic ADLs. Hierarchical regression 
permits examination of unique variance accounted for by the delayed recall subtest. The 
ADAS-cog11 was entered first, followed by item 12 (i.e., delayed recall), with the ADL 
measure as the dependent variable. There was a non-significant change in R2 with the 
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addition of delayed recall to the model, p = 0.88. The same procedures were performed 
again with the IADL measure as the dependent variable. There was a significant R2 
change from the first step (R2 = 0.39) to the second step (R2 = 0.40), p < .01. In this 
model, delayed recall accounts for an additional 1% of the variance in predicting IADLs, 
which is statistically significant. This confirms my hypothesis that delayed recall 
improves detection of the relationship between cognitive impairment and IADLs but not 
ADLs. Delayed recall accounts for an additional 1% of the variance, which is not a large 
increase but is a statistically significant gain. 
Treating the delayed recall subtest as an independent predictor in addition to the 
ADAS-cog11 yielded a statistically significant gain in prediction of IADLs. However, in 
clinical and research use, the delayed recall subtest score is generally combined with the 
other ADAS-cog subtest scores to generate a total score on the ADAS-cog12 rather than 
being examined independently. To be consistent with current clinical and research use of 
the ADAS-cog, a regression was conducted to examine variance accounted for by the 
ADAS-cog12 in predicting IADLs. This regression revealed an R2 of 0.40. Interestingly, 
the same amount of variance accounted for in predicting IADLs (40%) is gained whether 
adding delayed recall to the ADAS-cog total score (i.e., ADAS-cog12) or treating 
delayed recall as an independent factor and entering it into a hierarchical regression 
model after the standard ADAS-cog (i.e., ADAS-cog11). Collectively, these results 
provide evidence not only that the delayed recall subtest provides optimal information 
about AD-associated cognitive impairment in the mildest ranges of the disease, but it 
also improves the variance in IADLs for which the ADAS-cog can account.
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4. DISCUSSION AND CONCLUSIONS 
  
The results supported my expectations that delayed recall would best detect 
cognitive impairment in the mild ranges and that it would provide incremental 
information for predicting IADLs but not ADLs. The ADAS-cog12 fit a one-factor 
model, indicating that the subtests covary in a way that they measure one statistical 
factor or latent construct—in this case, a dimension of AD-associated cognitive 
impairment. IRT analyses revealed moderate-to-strong relationships between each 
ADAS-cog item and the latent construct (i.e., AD-associated cognitive impairment). 
Typically, a parameters range from 0 to 3 (Fraley et al., 2000; Gray-Little et al., 1997; 
Hambleton et al., 1991). In this study, the a parameters ranged from 1.65 to 2.86. Item 
12 (delayed recall) had an a parameter of 1.68, which indicates a moderately strong 
relationship with the latent construct.  
An examination of the item characteristic curves for the memory items indicate 
that these items have somewhat different patterns of functioning across the latent 
continuum (see Figure 3). Word recall provides optimal information from approximately 
-3.00 to 2.25 SDs, with the orientation and word recognition items capturing information 
best from approximately -1.50 to 0.50 and -2.25 to 1.00 SDs, respectively. Recall for test 
instructions provides the most information from approximately -0.75 to 1.00 SDs. 
Delayed recall functions optimally at the mildest end of the spectrum, capturing optimal 
information from approximately -3.00 to -1.00 SDs. Of all the ADAS-cog items, the 
delayed recall subtest is most sensitive to mild degrees of cognitive impairment. This is 
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consistent with prior research showing differential sensitivity of delayed recall measures 
in the earliest stages of AD (cf., Chen et al., 2000; Fleisher et al., 2007; Gallagher et al., 
2010; Pozueta et al., 2011; Rabin et al., 2009; Rami et al., 2012; Tabert et al., 2006). 
 Examining how the items function across the entire dimension of AD-associated 
cognitive impairment imparts rich information with implications for clinical and 
research utilization of the ADAS-cog. Currently, though, item scores are typically 
combined to generate a total score, which is then examined in research or clinical 
practice. Therefore, it is also critical to examine how the test as a whole functions across 
the range of cognitive impairment. Inspecting the test characteristic and information 
curves for the ADAS-cog12 (see Figures 4 and 5) reveals that it captures maximal 
information from approximately -1.00 to 1.50 SDs. The ADAS-cog11 seems to be most 
sensitive in the same range of AD-associated cognitive impairment, but on closer 
contrast of the two test information curves (see Figure 5), it is clear that the ADAS-
cog12 captures more information in the mild ranges than does the ADAS-cog11. This 
increase in information occurs between approximately -3.00 and 0.75 SDs, with greater 
incremental information toward the very mildest end of the dimension. The incremental 
information yielded by the ADAS-cog12 over that provided by the ADAS-cog11 is 
consistent with the fact that the delayed recall item provides maximal information in the 
mild range of cognitive impairment. By adding delayed recall to the standard 11-item 
ADAS-cog, the test as a whole gains information or sensitivity to cognitive impairment 
in the milder ranges of the disease. 
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This additional information about cognitive impairment also translates into 
improved prediction of IADLs. Delayed recall improves variance in IADLs accounted 
for by the ADAS-cog by 1%, whether including delayed recall in the total ADAS-cog 
score (i.e., ADAS-cog12) or treating it as an independent predictor in addition to the 
standard ADAS-cog total score. Accounting for an additional 1% of the variance in 
predicting IADLs may seem trivial. However, when predicting important outcomes such 
as ability to drive, properly handle finances, take medications, or operate an oven, it is 
critical to account for as much variance as possible. These functional impairments, while 
less disabling than ADLs, have great potential to inflict harm on oneself and others. 
Problems with driving may translate into increased traffic violations and motor vehicle 
accidents, while improper usage of medication can negatively impact one’s own health 
and could even be lethal. Moreover, financial mismanagement could lead to depleting 
one’s financial resources and forgetting to turn off an oven or stove creates a fire hazard. 
For these reasons, enhancing the ability to account for variance in IADLs is critical. 
Utilizing the delayed recall subtest increases the amount of variance in IADLs for which 
the ADAS-cog can account. 
This increase in predictive ability was found for IADLs but not ADLs, which 
was consistent with my expectations. Delayed recall provides maximal information in 
the mildest range of the disease, just as adding delayed recall to the standard ADAS-cog 
increases information in the mild range of the dementia spectrum. Patients with 
preclinical and early forms of AD commonly experience declines in their IADLs 
(Griffith et al., 2003; Perneczky et al., 2006), but deficits in ADLs do not occur until the 
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moderate-to-late stages of the disease (Hermann & Gauthier, 2008; Mendez & 
Cummings, 2003). Therefore, it is understandable that delayed recall, both 
independently and when added to the ADAS-cog, improves the prediction of only those 
functional outcomes that decline in the earlier stages of the disease, namely IADLs but 
not ADLs.  
In conclusion, delayed recall yields information about AD-associated cognitive 
impairment and strengthens the sensitivity of the ADAS-cog to information about 
cognitive dysfunction in the mild range of the disease. Moreover, this incremental 
information gained from the delayed recall subtest directly translates into increased 
prediction of deficits in IADLs, which are prone to declines early in the spectrum of AD. 
Future research should seek to extend these findings with longitudinal data and continue 
to explore how to further increase measurement precision and predictive power in the 
earliest stages of AD. As researchers continue to strive for earlier detection and better 
treatment of AD, delayed recall should be utilized as a sensitive measure of preclinical 
declines in memory and functional domains. As our understanding of prodromal 
symptoms of AD increases, we will move closer toward the ultimate goal of prevention. 
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